Back to search results

SYNERGY Study: Early Detection of Esophageal Squamous Cell Carcinoma

This study, called SYNERGY, is looking for better ways to find esophageal squamous cell carcinoma (ESCC), a type of cancer, early. Currently, ESCC is often found late, making it harder to treat. Researchers are testing a non-invasive (no surgery needed) blood test that looks at tiny genetic materials called cell-free microRNAs (cf-miRNAs) and exosomal microRNAs (exo-miRNAs) in your blood. The goal is to see if these can help detect ESCC at an earlier stage when it might be more curable. They will use different lab tests, including Small RNA sequencing, RT-qPCR quantification, and PCR-based validation, to identify these miRNAs. The study aims to enroll 600 adults, aged 18 to 90, who have been diagnosed with ESCC or are healthy controls without cancer. Success will be measured by how well the test can correctly identify people with ESCC.

Study design
This is an observational study, meaning researchers will collect and analyze samples without giving any new treatments. It aims to enroll 600 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, sensitivity, will be measured at study completion, which is an average of one year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07266363

Integrated Cf-miRNA and Exosomal miRNA Signature for Early Detection of Esophageal Squamous Cell Carcinoma

Recruiting
Not specifiedAges 18+Observational
City of Hope Medical Center
~600 participants
Updated 2026-07-07 on ClinicalTrials.gov
What's tested:Small RNA sequencing of exo- and cf-miRNAsRT-qPCR quantification of cf- and exo-miRNAs (SYNERGY assay)PCR-based validation (SYNERGY assay)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Sensitivity
Measured over At study completion, an average of one year

Conditions

ESCC

Explore related trials

Esophageal Squamous Cell Carcinoma

NCT07266363

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • City of Hope Medical Center

    Monrovia, Californiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Ajay Goel, PhD · PRINCIPAL_INVESTIGATOR · City of Hope Medical Center

Who to contact

Ajay Goel, PhD
[email protected]
626-218-3452
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults age 18 to 90 years
Histologically confirmed esophageal squamous cell carcinoma
No prior systemic therapy before sample collection
For control groups: absence of malignant disease

Exclusion

Lack of informed consent
Inadequate sample volume or RNA quality
Prior cancer within 5 years (except localized cancers)
Active systemic inflammation that may alter circulating RNA profiles

What this trial measures

  • SensitivityAt study completion, an average of one year

    Comparison of Pathological Diagnosis and the SYNERGY Assay